Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study-Reference-Cited by-同舟云学术

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Published:2020-11 Issue:11 Volume:21 Page:1500-1512
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Xu Jianming,Shen Lin,Zhou Zhiwei,Li Jie,Bai Chunmei,Chi Yihebali,Li Zhiping,Xu Nong,Li Enxiao,Liu Tianshu,Bai Yuxian,Yuan Ying,Li Xingya,Wang Xiuwen,Chen Jia,Ying Jieer,Yu Xianjun,Qin Shukui,Yuan Xianglin,Zhang Tao,Deng Yanhong,Xiu Dianrong,Cheng Ying,Tao Min,Jia Ru,Wang Wei,Li Jing,Fan Songhua,Peng Mengye,Su Weiguo

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States;Dasari;JAMA Oncol,2017

2. Whole-genome landscape of pancreatic neuroendocrine tumours;Scarpa;Nature,2017

3. Genetic and epigenetic drivers of neuroendocrine tumours (NET);Di Domenico;Endocr Relat Cancer,2017

4. The genomic landscape of small intestine neuroendocrine tumors;Banck;J Clin Investig,2013

5. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors;Halperin;Annu Rev Med,2015

Cited by 127 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of typical and atypical metastatic lung carcinoids: present and future perspectives;Clinical and Translational Oncology;2024-08-07

2. Update in the management of gastroenteropancreatic neuroendocrine tumors;Cancer;2024-07-16

3. Case report: Metastatic refractory undifferentiated small round-cell sarcoma successfully treated with surufatinib and camrelizumab;Frontiers in Oncology;2024-07-11

4. Exploring the multifaceted antitumor activity of axitinib in lung carcinoids;Frontiers in Endocrinology;2024-07-10

5. European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well‐differentiated small intestine neuroendocrine tumours;Journal of Neuroendocrinology;2024-07-08